Please select the option that best describes you:
In an early stage breast cancer post neoadjuvant chemotherapy, do you repeat ER/PR and HER2 status on the surgical specimen if there is residual disease?
The surgeons at our institution are asking for repeat markers but I am not aware of any data or guidelines to support this.
Answer from: Medical Oncologist at Academic Institution
It can be more nuanced than always repeating all the receptors. If there is residual disease after NAC, and the cancer is grade 3, I do feel it is worthwhile to at least repeat HER2. After all, we have good options for reducing the risk of recurrent HER2+ disease in the residual disease after NAC se...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
Repeat markers after neoadjuvant therapy can be helpful clinically. Certainly if initially, ER and/or HER2 are negative, will repeat on residual disease. Looking for a target if we don’t have one, rather than disqualifying an initial target.
As a general principle, a biopsy is often just a sm...
Answer from: Medical Oncologist at Community Practice
Keeping the same theme—a woman in her 50s with stage IIB (T2N1G3) invasive ductal carcinoma initially ER/PR-positive and HER2 2+ with FISH-negative results, treated with neoadjuvant dose-dense AC followed by paclitaxel, who subsequently underwent mastectomy with good response but had residual ...